Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 14.75% | Reduce −2.9% | 1,831,035 | $97.24 | $178M | −54,776 | −$17M |
| Revance Therapeutics | 14.06% | Reduce −0.3% | 5,270,209 | $32.21 | $170M | −13,400 | +$72M |
| UTHR - United Therapeutics | 11.64% | Add +0.3% | 627,514 | $223.96 | $141M | +2,100 | −$33M |
| FOLD - Amicus | 9.67% | Add +0.3% | 10,524,022 | $11.09 | $117M | +30,300 | −$11M |
| BIIB - Biogen | 8.78% | Add +0.3% | 381,282 | $278.03 | $106M | +1,200 | +$756K |
| INSM - Insmed | 8.32% | Add +0.3% | 5,889,491 | $17.05 | $100M | +18,200 | −$17M |
| Staar Surgical | 7.14% | Add +8.6% | 1,347,322 | $63.95 | $86M | +107,245 | +$26M |
| PRTA - Prothena | 6.68% | Add +0.3% | 1,663,777 | $48.47 | $81M | +5,200 | −$19M |
| ACAD - Acadia Pharmaceuticals | 3.75% | Add +1.2% | 2,405,793 | $18.82 | $45M | +29,424 | +$7M |
| Sage Therapeutics | 2.99% | Add +0.4% | 859,517 | $41.96 | $36M | +3,000 | +$3M |
| EHTH - Ehealth | 2.09% | Add +8.2% | 2,689,379 | $9.36 | $25M | +204,900 | +$13M |
| ALGN - Align Technology | 2.07% | Hold | 74,605 | $334.14 | $25M | — | — |
| Karyopharm Therapeutics | 1.83% | Add +0.4% | 5,675,876 | $3.89 | $22M | +20,200 | +$3M |
| ALKS - Alkermes | 1.41% | Hold | 603,400 | $28.19 | $17M | — | — |
| SNDX - Syndax Pharmaceuticals | 1.07% | Hold | 612,600 | $21.12 | $13M | — | — |
| Provention Bio | 0.78% | Hold | 390,800 | $24.10 | $9M | — | — |
| ANAB - Anaptysbio | 0.78% | Add 0.0% | 431,224 | $21.76 | $9M | +200 | −$4M |
| Gossamer Bio | 0.36% | Add +9079.2% | 3,465,152 | $1.26 | $4M | +3,427,402 | +$4M |
| CYTK - Cytokinetics | 0.33% | Hold | 111,717 | $35.19 | $4M | — | — |
| TVTX - Travere Therapeutics | 0.31% | Hold | 166,069 | $22.49 | $4M | — | — |
| VNDA - Vanda Pharmaceuticals | 0.27% | Reduce −55.6% | 482,697 | $6.79 | $3M | −604,910 | −$5M |
| Kezar Life Sciences | 0.17% | Hold | 656,200 | $3.13 | $2M | — | — |
| NVCR - Novocure | 0.16% | New | 32,790 | $60.14 | $2M | +32,790 | +$2M |
| Gritstone Oncology | 0.15% | Hold | 666,127 | $2.78 | $2M | — | — |
| ALDX - Aldeyra Therapeutics | 0.13% | Hold | 160,800 | $9.93 | $2M | — | — |
| MIRM - Mirum Pharmaceuticals | 0.13% | Hold | 64,700 | $24.02 | $2M | — | — |
| RLMD - Relmada Therapeutics | 0.10% | New | 542,100 | $2.26 | $1M | +542,100 | +$1M |
| Holding | 0.04% | Hold | 27,100 | $16.42 | $445K | — | — |
| Peak Bio | 0.03% | Hold | 497,528 | $0.6314 | $314K | — | — |
| URGN - Urogen Pharma | 0.02% | Hold | 24,500 | $9.24 | $226K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | 0.05% | Exit | 0 | $2.71 | $544K | −200,919 | −$544K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2